Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies

Elisabetta Bianchi (1) , Matteo Vecellio (2, 3) , Lars Rogge (1)

1 Immunorégulation - Immunoregulation
2 University of Oxford
3 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico

Editorial on the Research Topic Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies Chronic inflammatory diseases (CID) are clinically heterogeneous conditions that share common inflammatory pathways and derive from aberrant immune responses. The implication of the interleukin-23/interleukin-17 (IL-23/IL-17) axis in several CID is supported by studies in animal models of autoimmune disease (1, 2) and by the genome-wide association studies (GWAS) finding that several of the non-MHC loci genetically linked to Crohn’s disease, psoriasis, and axial spondyloarthritis (axSpA), are associated with genes in this pathway (IL23R, IL12B, IL6R, IL1R2, RORC, RUNX3, TYK2, JAK2, CARD9) (3–5).

Keywords: chronic inflammatory diseases; spondyloarthritis; interleukin-23; interleukin-17; psoriasis

Domains: Life Sciences [q-bio]; Immunology

Elisabetta Bianchi, Matteo Vecellio, Lars Rogge. Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies. Frontiers in Immunology, 2021, 12, pp.770275. ⟨10.3389/fimmu.2021.770275⟩. ⟨pasteur-03497758⟩